Home Pharma Supply Chain Transformation: Challenges, Risks and Future Strategies (2025 Outlook)

Pharma Supply Chain Transformation: Challenges, Risks and Future Strategies

Foreword 

The pharmaceutical industry’s supply chain is not merely about transporting drugs; it is truly a lifeline connecting patients to critical, life-saving medicines where even minor delays can have major consequences. This white paper is being published at a time when transformation in this space is not merely advantageous but essential for survival. 

The pharma industry and its global supply chain stand at a critical juncture where traditional models are being challenged by an unprecedented convergence of global forces. The COVID-19 pandemic served as a stark reminder of our industry’s vulnerabilities. Today, we face an even more complex landscape where sustainability mandates, digital transformation imperatives and evolving patient expectations demand a fundamental reimagining of pharmaceutical logistics. Additionally, this needs to happen amid challenges such as geopolitical tensions, increasing regulatory complexity, the explosive growth of personalised medicine and the persistent threat of counterfeit drugs.

The time for incremental change has passed. The path forward requires bold leadership, strategic investment and collaborative partnerships across the entire ecosystem. The insights presented here illuminate both the challenges and the remarkable opportunities ahead. 

As we navigate towards a future where supply chains must be simultaneously more agile, sustainable and compliant, the companies that embrace digitalisation, prioritise environmental responsibility and maintain unwavering manufacturing and distribution standards will not only survive but thrive. We hope that this paper serves as a guide in helping your company get there.

Authors:

• Alexandre de Beaupuy, Development Director for Health, Beauty and Luxury Goods, FM Logistic
• Pawel Janicki, Business Development Director, FM Logistic Central Europe

Executive Summary

The pharmaceutical industry is facing an era of profound disruption and transformation. The sector’s supply chain – the critical conduit that ensures the safe and timely delivery of life-saving medicines – is under pressure on multiple fronts and must adapt rapidly to a changing operating environment. Agile, digitally enabled, sustainable and resilient supply chains that meet these challenges will have a major competitive advantage.

1. Under the Microscope: The Forces Reshaping Pharma Supply Chains

The pharmaceutical supply chain faces a complex yet opportunity-rich environment influenced by geopolitical headwinds and related bottlenecks, a growing preference for personalised medicine whose market is expected to be worth over $1 trillion by 2033, stricter regulations, and the rise of counterfeit drugs, which is estimated to be a $400 billion annual industry.

2. Forging Ahead: Imperatives for a Future-Ready Pharma Supply Chain

Amid these challenges, three vital levers will define the resilience and success of future pharmaceutical supply chains: Digital transformation with the help of technologies like AI to create a proactive, intelligent network; Environmental responsibility, driven both by regulatory mandates as well as consumer expectations; and, Compliance expertise, which remains an absolute “must have” and will still prove to be a crucial differentiator.  

3. A Call to Action: Reimagining the Pharma Supply Chain

This period of disruption presents significant opportunities for those bold enough to reimagine the pharmaceutical supply chain. Next-generation supply chains – agile, digitally enabled, sustainable and compliant – will offer a crucial competitive advantage. Companies that invest in these capabilities will not only overcome today’s challenges but can also attain a leadership position with faster drug launches, improved patient outcomes and robust defences against future disruptions.

1. Under the Microscope: Forces Reshaping Pharma Supply Chains

A literal lifeline

The pharmaceutical supply chain is more than a logistical necessity – it is the backbone that determines whether life-saving medicines reach patients safely, efficiently and on time. Timely delivery is non-negotiable with even minor delays or temperature deviations rendering products ineffective. 

These “business as usual” complexities are being compounded as the industry deals with multiple challenges.

Evolving challenges in the pharma supply chain

Challenge 1: Geopolitics, trade wars and tariffs

The US-China trade war has disrupted global pharmaceutical supply chains and impacted patients and healthcare systems worldwide by raising drug prices, straining collaborations between researchers in the two countries and delaying innovation., This has caused supply shortages and forced strategic shifts in manufacturing and sourcing practices.

  • Rising costs: The US has imposed steep tariffs on pharma imports, including Chinese APIs – which are used in about 40% of US generic drugs – with rates reaching up to XX%, sharply increasing production costs for generic drug manufacturers in the US and bringing higher drug prices for American consumers. This has led many firms to alter project plans, stockpile supplies and consider conducting testing locally.
  • Shifting supply lines: Pharma companies are expected to react by moving manufacturing within national borders or closer to their home markets. Already some Swiss giants, which do a third of their sales in the US, are shipping as many products as possible to the country before the tariff hikes take effect. Others are spending hundreds of millions of dollars to diversify production. 
  • New cross-border trends: Some EU-based clients are importing APIs from markets like India to manufacture the drugs in the EU, where previously they would import semi- or fully finished products. This has implications for third-party logistics (3PL) providers, which need to adapt to provide the right infrastructure to store those APIs and the finished goods until they can be sold. 

Challenge 2: COVID-19

The pandemic exposed the fragility of the global pharma supply chain. Seventy percent of pharma companies highlighted supply chain vulnerabilities during the pandemic, indicating a need for better preparedness. 

  • Increased supply chain complexity: In response to the vulnerabilities exposed by the pandemic, the number of supply chain companies serving the pharma industry has risen, with investments to build resilience. Additionally, the pandemic boosted the industry’s use of technology to address specific gaps like automating labour-intensive tasks and meeting the need for specialised, lightweight temperature-controlled containers.
  • Reshaped networks: The pandemic also triggered other key changes: greater adoption of omni-channel distribution networks and a preference for larger inventories to create buffer stocks. 

Challenge 3: The drive for greater sustainability

The industry’s move towards sustainable practices is being led by the beauty and luxury sub-sector to serve its increasingly environmentally conscious customer base. 

  • The growing demand for sustainable practices: With regulators, particularly in the European Union, providing a crucial push, beauty and luxury product makers are adopting various sustainability strategies, such as using natural ingredients, ethically sourcing materials and sharing details about their supply chain and labour practices to win consumers’ trust. They are also adopting innovative packaging technologies to cut waste, and acquiring certifications to validate claims and demonstrate impact.
  • Pharma sector playing catch-up: While the broader pharma industry continues to lag in this respect, it is likely to adopt the beauty and luxury industry’s playbook to catch up on key sustainability metrics.

Challenge 4: Counterfeit drugs

The fake medicine industry is among the sector’s biggest problems – estimated to be worth more than US$400 billion a year. Underlining the scale of the problem is the size of the market for detecting counterfeit drugs, which is estimated to be about US$1.5 billion and expected to double in size by 2037.

  • Addressing a major health risk: With one in 10 medical products estimated to be counterfeit or substandard in low- and middle-income countries, and the problem only set to worsen with the growth of online pharmacies, this is a major challenge that needs to be addressed, ideally via solutions like serialisation, which is a key weapon in combating fake medicine as it enhances the traceability of drugs across the supply chain. Serialisation, however, comes with its own set of challenges including the availability and management of data and technology to support the process, regulatory compliance and training personnel.

Challenge 5: The growth of personalised medicine and new drugs

Some estimates peg the personalised medicine market at US$1.2 trillion by 2033, up from about US$570 billion in 2024, making this a trend that the pharma industry and 3PL providers cannot ignore. Furthermore, new drug types such as mRNA-based therapeutics and cellular and gene therapies are emerging. These not only require special manufacturing processes; they also need better handling and storage. That requires a ramp-up in cold-chain logistics or temperature-controlled transport infrastructure – which few operators can offer.

The personalised medicine market

  • New products, new supply chains: These new products call for supply chains significantly different to existing ones; that means adapting to transport a new range of products, and not just to hospitals and clinics as in the past, but to individuals too. This adds a new level of complexity, both at the source and close to the destination to solve the last-mile delivery problem.

Challenge 6: Growing regulatory complexity

The storage and transport of drugs has long been subject to stringent regulations, and for good reason – people’s lives depend on them. With regulatory oversight starting at the point of moving APIs,the raw material used to produce drugs, it makes for a highly demanding regulatory and compliance burden. 

  • More than just GDP: While the industry’s Good Distribution Practices provide a standardised framework, service providers must adhere to other regulations governing metrics like product serialisation and temperature control as well as a variety of market-specific regulations.
  • A patchwork of rules: Regional licensing and regulatory requirements often vary significantly. That can make complying with the cross-border patchwork of regulations onerous. In the US, for example, the Food & Drug Administration (FDA) has sought to create a national standard for licensing wholesale drug distributors and logistics providers. In the EU, the European Medicines Agency evaluates, supervises and monitors the flow of medicines while member states’ national authorities are responsible for licensing and inspecting pharmaceutical companies to ensure compliance with EU regulations. In Asia, regulations mirror the region’s economic and cultural diversity with one common thread: Most governments closely regulate the industry and its 3PL providers. Laws comprehensively govern the production, distribution and sale of pharma products, as well as intellectual property rights and the interplay between original and generic drugs.
  • Slow progress on harmonisation: Work is underway to harmonise cross-border regulatory approaches in certain areas. The WHO, for instance, develops international regulatory standards through extensive consultation covering areas like stability, packaging and storage., These standards can then serve as benchmarks for national and regional authorities, facilitating access to medicines and easing the compliance burden.
  • Reclassifications complicate compliance: Drugs are also subject to reclassifications based on an evolving understanding of their efficacy and side-effects over time, or regional regulators can call for certain drugs to be termed as medical devices. This has implications for how the industry handles, labels, stores and moves these reclassified products, as well as returns and recalls. 

Challenge 7: Bottlenecks in manufacturing and distribution

The industry is also dealing with challenges that constrict the supply chain at crucial junctures, creating last-mile delivery difficulties. That includes shortages of raw materials like APIs as well as of secondary products like bottles and vials, which can be due to various reasons including geopolitics, trade wars, tariffs and pandemics. 

  • Limited infrastructure: Other bottlenecks include the limited availability of distribution networks with the necessary infrastructure, such as temperature-range capabilities to transport an evolving range of drugs – a particular challenge in emerging and less-developed markets, leading to issues like product spoilage and creating safety risks for patients and financial losses for companies. This challenge is further complicated by the irregular processing times and supply flows of personalised medicines, whose nature means they lack the efficiencies of scale of generic medicines.

2. Forging Ahead: Imperatives for a Future-Ready Pharma Supply Chain

Considering the challenges outlined above, pharma supply chains must evolve to become more agile, sustainable and compliant. Technology will be at the heart of next-gen supply chains, ensuring pharma companies can green their manufacturing-related processes, transport and distribution networks, and address the last-mile delivery challenge. 

Adding strategic value

At each stage of the production and distribution process, pharmaceutical companies will be looking for supply chain partners that can add strategic value to their operations, with capabilities that include:

  • Specialised storage and distribution capabilities: 3PL providers will need to offer a range of inventory management services, including temperature-controlled storage and transportation, to maintain product stability. They must offer the specialised equipment and processes needed to accurately weigh samples and ensure precise measurements of formulations – a quality control service that is crucial even at pre-manufacturing stages such as R&D.
  • Compliance support: 3PL providers will increasingly be expected to help pharma companies stay abreast of and comply with an evolving raft of local, national and regional regulations. This means 3PL providers must monitor and alert clients to specific market trends, such as demand fluctuations and the use of technological and sustainability tools, and assist them to adapt these aids into their operations. That in turn requires that 3PL providers recruit staff who have the appropriate expertise, certifications and licences needed to assist clients in audit and reporting to ensure they remain compliant.
  • Advanced distribution solutions: A 3PL provider’s core function is to handle the challenges of maintaining product integrity while transporting life-saving drugs across long distances. That requires solutions like packages that maintain a stable temperature, with sensors and data-loggers reporting material changes in temperature to the end-user to help determine the effectiveness and usability of a drug. Additionally, GPS tracking will become a necessity to address the last-mile challenge of delivering sensitive drugs to pharmacies worldwide. Next-gen supply chain providers will also be expected to help pharma companies deal with the scourge of counterfeit drugs, including by verifying product authenticity and ensuring the veracity of products with the use of QR codes and barcodes.

What makes a next-gen pharma supply chain? 

The exemplary pharma supply chains of tomorrow will also share defining characteristics and best practices:

Sustainability metrics

  • Measuring sustainability is a must: Sustainability has become a central feature of next-gen supply chains, and will become more so – with green business strategies becoming more important to pharma executives in recent years as they adapt to an increasingly eco-minded client base and seek to meet evolving regulations: At CPHI Barcelona in 2023, 93% of industry leaders said it was important or extremely important to have visibility on their supply chain partners’ sustainability record.
  • Scope 3 emissions will sharpen the focus: Among the most challenging metrics are those related to Scope 3 emissions, whose rules require companies to track the emissions of their entire supply chain. 3PL providers can help clients by monitoring and reporting on those emissions, and by offering solutions like sustainable materials for packaging, green distribution networks from first mile to last, and deploying inclusive recruitment practices. Specific steps include reducing CO2 emissions in warehouses through green energy sources, diversifying transportation fleets with hybrid, electric, gas or hydrogen-powered trucks, and reducing packaging waste.  

Cutting-edge technology

  • Enhanced use of existing technologies: Next-gen supply chains already rely heavily on RFID and Near Field Communication, which boost warehouse and distribution efficiency by enabling rapid scanning and detailed tracking of pharmaceutical products. Additionally, IoT-enabled tracking devices monitor metrics like location, temperature, humidity and physical shocks in real-time to ensure product integrity during transit. 

    Going forward, 3PL providers will need to integrate sensor data with AI analytics and robotics to streamline warehousing and inventory management practices, and allow for continuous monitoring and rapid response to deviations that could compromise drug quality. This integration also ensures the integrity of temperature-sensitive products, such as vaccines and biologics, throughout the supply chain, reducing losses and maintaining compliance with good distribution practices.

  • Better product traceability and regulatory compliance: Distributed ledger technology, or blockchain, offers a tamper-proof record of every transaction and movement of pharmaceutical products from manufacturing through distribution to the end consumer. This transparent and immutable record ensures the authenticity of drugs, preventing counterfeit products from entering the supply chain and facilitates compliance with stringent regulatory requirements by providing clear audit trails and real-time reporting capabilities.  

  • Better predictive analytics: Also crucial are data and AI, which can be used to enhance predictive analytics capabilities – ensuring better forecasting of demand and optimising transport routes; these can also flag potential disruptions stemming from natural disasters and geopolitical events. This predictive capability enables proactive decision-making, preventing stock shortages and reducing waste while improving service levels. 
  • AI for optimisation and automation: AI also helps to automate routine tasks and optimise production parameters such as temperature and raw material variability. One example is the use of AI-powered virtual assistants to monitor manufacturing lines in real time, predict equipment failures and schedule maintenance; that leads to improvements in equipment effectiveness and significant productivity gains.
  • GenAI use cases to expand: 3PL providers focused on the future are assessing use cases around new developments like GenAI, which some estimates suggest could yield as much as US$110 billion in economic value annually for the pharma industry. While it is difficult to accurately assess GenAI’s impact, it is certain that companies will invest large sums working out how best it can be deployed.

Cross-sector best practices 

  • Multi-sectoral expertise: Finally, leading 3PL providers already help clients by sharing the benefits they glean from their cross-sector experience – applying best practices and solutions in other logistics-reliant sectors like consumer goods and ecommerce to the pharma industry – and this will become even more of a competitive advantage going forward. These best practices include handling solutions like specialised forklifts, which were initially tested for e-commerce, in pharma warehouses, as well as services like hospital stock-planning and the direct distribution of expensive drugs.

3. A Call to Action: Reimagining the Pharma Supply Chain

The pharmaceutical industry and its supply chain network are at a crossroads, facing unprecedented complexities and challenges along with opportunities to explore and capitalise on new avenues of growth. Geopolitical tensions, evolving regulatory demands, the rising threat of counterfeits and the rapid growth of personalised medicine underscore the urgent need for transformative action.

To navigate this landscape, the industry must embrace a multi-pronged strategy centred on innovation, collaboration, sustainability and adaptability. Our recommendations include:

  • Investment in cutting-edge technologies is essential. AI and blockchain are no longer optional; they are critical tools for enhancing supply chain visibility, ensuring product authenticity and optimising logistics. AI-driven predictive analytics help companies expedite new drugs to market, anticipate disruptions and streamline transportation and distribution routes, while blockchain provides traceability to combat counterfeit drugs and accelerate recall processes.
  • Advanced cold-chain solutions must be prioritised to safeguard temperature-sensitive medicines, especially as growing demand for personalised therapies requires increased capacity for more precise handling and last-mile delivery capabilities. These technologies can collectively build resilience and operational excellence, converting supply chains from cost centres into strategic assets.
  • Equally important is fostering collaboration among all stakeholders – pharma companies, logistics providers, regulators and technology partners. Bottlenecks in raw materials, distribution infrastructure and regulatory compliance can only be addressed effectively via coordinated efforts that leverage shared data and align incentives. Collaborative networks also facilitate near-shoring and regional production strategies, helping to mitigate geopolitical risks and supply disruptions, while strategic partnerships can accelerate the adoption of innovative practices and create scalable solutions that benefit the entire ecosystem, enhancing the sector’s agility and responsiveness.
  • Sustainability must be embedded as a core pillar of supply chain operations. As regulatory bodies and consumers increasingly demand greener practices, pharma companies and logistics providers have a responsibility and opportunity to reduce their environmental footprint. Initiatives like powering warehouses with green energy, deploying alternative-fuel fleets, using sustainable packaging practices and waste reduction not only contribute to global net-zero goals; they enhance brand reputation and operational efficiency. The broader pharma industry can draw valuable lessons from sub-sectors like beauty and luxury, which lead in sustainability innovation and transparency. 
  • Proactively adapting to the evolving regulatory landscape is another imperative. Compliance with Good Distribution Practices, such as product serialisation, temperature control standards and country-specific regulations, requires agility and expertise. Companies that develop robust regulatory intelligence and integrate compliance into their operational DNA will gain a competitive advantage, reduce risks and facilitate faster market access for new therapies.

Together, these steps will safeguard the delivery of life-saving medicines and position the pharmaceutical supply chain as a force for delivering positive global health outcomes.

The time to act is now – not least because building a future-ready pharma supply chain is a collective responsibility that will have profound implications for countless millions worldwide.

Footnotes

1 https://www.novaoneadvisor.com/report/personalized-medicine-market

2 https://www.openaccessgovernment.org/why-are-illegal-pharma-markets-still-prevalent-today/105600/

3 https://www.reuters.com/business/healthcare-pharmaceuticals/china-pharma-projects-disrupted-by-sino-us-tensions-2025-06-17/

4 https://www.geneonline.com/trumps-trade-war-shake-up-how-u-s-tariffs-could-disrupt-global-pharma/

5 https://www.biospectrumasia.com/analysis/25/25790/trumps-tariff-war-threatens-to-disrupt-pharma-supply-chain.html

6 https://www.delveinsight.com/blog/us-tariffs-2025-impact-healthcare-pharma-strategies

7 https://www.reuters.com/business/healthcare-pharmaceuticals/china-pharma-projects-disrupted-by-sino-us-tensions-2025-06-17/

8 https://www.cnbc.com/2025/07/11/trump-200percent-pharma-tariffs-threaten-to-push-up-drug-prices-hit-margins.html

9 https://www.pharmaceutical-technology.com/features/are-european-biopharma-manufacturers-nearshoring/

10 https://supplychaindigital.com/operations/supply-chain-challenges-prompts-biopharma-nearshoring-moves

11 https://www.europeanpharmaceuticalreview.com/news/133953/pharma-supply-chain-still-highly-vulnerable-to-covid-19-pandemic-says-research/

12 https://beamberlin.com/log/the-pandemics-impact-on-the-pharmaceutical-supply-chain/

13 https://www.whitecase.com/insight-alert/luxury-and-esg-navigating-new-eu-legal-landscape-fashion-and-luxury-goods-industry

14 https://www.cas.org/resources/cas-insights/the-rise-of-natural-ingredients-for-cosmetics

15 https://www.fsrl.co.uk/resources/blog/the-future-of-sustainable-luxury-fashion-in-2025/

16 https://www.thewalkmag.com/blog-2-3/the-push-for-supply-chain-transparency-in-luxury-fashion

17 https://www.cosmeticsdesign-asia.com/Headlines/Promotional-features/sustainable-inclusive-beauty-innovation-trends-2025/

18 https://www.fsrl.co.uk/resources/blog/the-future-of-sustainable-luxury-fashion-in-2025/

19 https://www.who.int/news-room/photo-story/detail/urgent-health-challenges-for-the-next-decade

20 https://www.researchnester.com/reports/counterfeit-drug-detection-device-market/6470

21 https://www.who.int/news/item/28-11-2017-1-in-10-medical-products-in-developing-countries-is-substandard-or-falsified

22 https://www.cas.org/resources/cas-insights/counterfeit-drugs

23 https://slcontrols.com/serialisation-pharmaceutical-industry-need-know/

24 https://nubinno.com/what-are-the-challenges-of-serialization/

25 https://www.novaoneadvisor.com/report/personalized-medicine-market

26 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02444-3/fulltext

27 https://www.pharmaceutical-technology.com/buyers-guide/cold-chain-storage-distribution/

28 https://www.gmp-compliance.org/gmp-news/gdp-compliant-transport-of-apis-what-needs-to-be-considered

29 https://www.bizzmine.com/en/blog/the-most-essential-criteria-for-gdp-compliance-in-pharma-logistics

30 https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/fda-announces-proposed-rule-national-standards-licensure-wholesale-drug-distributors-and-third-party

31 https://www.ema.europa.eu/en/about-us

32 https://www.ema.europa.eu/en/partners-networks/eu-partners/eu-member-states/national-competent-authorities-human

33 https://www.tilleke.com/insights/pharmaceutical-industry-asia/13/

34 https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/guidelines/regulatory-standard

35 https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/norms-and-standards-for-pharmaceuticals/guidelines

36 https://www.gov.uk/guidance/medicines-reclassify-your-product#overview

37 https://www.nsf.org/knowledge-library/fda-drug-device-transition

38 https://www.chemistryworld.com/news/explainer-why-drug-shortages-happen-and-how-can-we-reduce-them/4019960.article

39 https://www.ismworld.org/supply-management-news-and-reports/news-publications/inside-supply-management-magazine/blog/2020-09/when-bottles-as-in-medical-vials-become-the-bottleneck/

40 https://www.mckinsey.com/industries/life-sciences/our-insights/four-ways-pharma-companies-can-make-their-supply-chains-more-resilient

41 https://www.ifc.org/en/what-we-do/programs-projects/sustainable-cooling/sustainable-cooling-of-cold-chains

42 https://www.business-standard.com/industry/news/pharma-companies-on-track-with-qr-codes-to-combat-counterfeit-drugs-124071700793_1.html

43 https://www.contractpharma.com/exclusives/cphi-barcelona-2023-sustainability-commitments-accelerating-in-pharma-supply-chain/

44 https://www.carbontrust.com/our-work-and-impact/guides-reports-and-tools/what-are-scope-3-emissions-and-why-do-they-matter

45 https://www.supplychainbrain.com/blogs/1-think-tank/post/41231-why-pharma-companies-must-prioritise-track-and-trace-tech-in-2025

46 https://www.pharmaceuticalonline.com/doc/the-technologies-poised-to-transform-the-pharmaceutical-supply-chain-in-and-beyond-0001

47 https://eaststreetpharmacy.com/the-impact-of-blockchain-technology-on-pharmaceutical-supply-chains.html

48 https://itsoli.ai/enhancing-drug-traceability-with-blockchain-and-ai-in-supply-chain-management/

49 https://sensos.io/resources/technology-innovation/pharma-logistics-2025-navigating-tariff-turmoil-and-ensuring-cargo-integrity/

50 https://www.mckinsey.com/industries/life-sciences/our-insights/generative-ai-in-the-pharmaceutical-industry-moving-from-hype-to-reality

Frequently Asked Questions

What are the main challenges in pharmaceutical supply chains?

The main challenges include geopolitical disruptions, regulatory complexity, counterfeit drugs, sustainability requirements and the growth of personalised medicine.

How is AI transforming pharma supply chains?

AI enables predictive analytics, demand forecasting, route optimisation and real-time monitoring of temperature-sensitive drugs.

Why is sustainability important in pharma logistics?

Sustainability is driven by regulatory pressure and consumer expectations, requiring companies to reduce emissions and improve transparency.